Waldenström Macroglobulinemia (WM) is a unique, low grade, IgM lymphoplasmacytic
lymphoma with a heterogeneous clinical course. A paucity of high-grade evidence from …

We here describe a novel method for MYD88 L265P mutation detection and minimal
residual disease monitoring in Waldenström macroglobulinemia, by droplet digital …

Waldenström's macroglobulinemia (WM) is a rare, incurable hematologic disorder with a
relatively indolent course in a majority of the patients. Despite this, a significant proportion of …

Waldenström macroglobulinemia (WM) is an immunoglobulin M‐associated lymphoma, with
majority of cases demonstrating MYD88 locus alteration, most commonly, MYD88L265P …

Ibrutinib‐related data in Waldenström macroglobulinaemia (WM) remain sparse, particularly
outside of trials. We report on 80 patients [previously treated, n= 67 (84%), treatment‐naïve …

Comparative data guiding initial therapy for Waldenström macroglobulinemia (WM), an
infrequently encountered non‐Hodgkin lymphoma, are sparse. We evaluated three …

华氏巨球蛋白血症的临床特征及预后：单中心临床数据报道- PMC Back to Top Skip to main
content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main …

Abstract Purpose of Review The treatment of Waldenström macroglobulinemia (WM) has
evolved over the past decade. With the seminal discoveries of MYD 88 and CXCR warts …

Abstract Purpose of Review Recent advances the genomic profiling of patients with
Waldenström macroglobulinemia (WM) have led to the identification of novel therapeutic …

We report here two cases of Waldenstrom's macroglobulinemia (WM), one with central
nervous system (CNS) symptoms and severe retinopathy and one with renal failure. In both …